Ken Griffin Oramed Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.21 - $2.63 $8,840 - $10,520	4,000 New	4,000 $9,000
Q1 2024 May 15, 2024	SELL	$2.18 - $3.58 $2,834 - $4,654	-1,300 Reduced 13.54%	8,300 $24,000
Q4 2023 Feb 14, 2024	SELL	$1.71 - $2.57 $8,208 - $12,336	-4,800 Reduced 33.33%	9,600 $22,000
Q3 2023 Nov 14, 2023	SELL	$2.51 - $3.55 $47,940 - $67,805	-19,100 Reduced 57.01%	14,400 $37,000
Q2 2023 Aug 14, 2023	BUY	$2.12 - $4.47 $3,816 - $8,046	1,800 Added 5.68%	33,500 $119,000
Q1 2023 May 15, 2023	SELL	$1.93 - $13.1 $74,691 - $506,970	-38,700 Reduced 54.97%	31,700 $69,000
Q4 2022 Feb 14, 2023	SELL	$5.88 - $12.03 $95,844 - $196,089	-16,300 Reduced 18.8%	70,400 $846,000
Q3 2022 Nov 14, 2022	SELL	$4.6 - $9.91 $1,380 - $2,973	-300 Reduced 0.34%	86,700 $562,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $86.6M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.